News
17 May 2016

Kexim invests in US drug developer

Region:
Americas, Asia-Pacific

The Export-Import Bank of Korea (Kexim) is investing $10 million in Kolon Group's US-based drug-developing subsidiary TissueGene. It is Kexim's first equity investment in a drug developer.

Exclusive subscriber content…

If you are a TXF subscriber, please login to continue reading

Login

Not yet a subscriber? Join us today to continue accessing content without any restrictions

View our subscription options

Or to request access to TXF Intelligence contact us

Request Access

You might also like


Perspective
14 August 2026

ECA volumes cruise well in H1

With a total aggregated debt volume of $70.8 billion in the first half this year, ECA activity was solid but not necessarily in the sectors it needs to be to realise the race...

Perspective
21 August 2026

Agencies shift towards reconstruction in Ukraine

Ukraine is no longer waiting for peace to finance its recovery. But generous terms, layered guarantees, war-risk cover, fund anchors and public balance sheets are taking the...